Merlin is a tumour suppressor involved in the development of a variety of tumours including mesotheliomas. Neurofibromatosis type 2 (NF2), a dominantly inherited tumour disease, is also caused by loss of merlin. NF2 patients suffer from multiple genetically well-defined tumours, schwannomas are most frequent among those. Using our in vitro model for human schwannoma, we found that schwannoma cells display enhanced proliferation because of the overexpression/activation of platelet-derived growth factor receptor and ErbB2/3, increased cell-matrix adhesion because of the overexpression of integrins, and decreased apoptosis. Mechanisms underlying schwannomas basal proliferation and cell-matrix adhesion are not understood. Here, we investigated insulin-like growth factor-binding protein-1 (IGFBP-1), which is expressed and released from central nervous system tumours and strongly overexpressed in schwannoma at the mRNA level. IGFBP-1 acts via b1-integrin and focal-adhesion-kinase (FAK), which are strongly overexpressed and basally activated in schwannoma. Using short hairpin RNA knockdown, small inhibitors and recombinant IGFBP-1, we demonstrate that schwannoma cells, in contrast to Schwann cells, release IGFBP-1 that activates the Src/FAK pathway, via integrin b1, potentiating schwannoma's proliferation and cell-matrix adhesion. We show that FAK localizes to the nucleus and Src triggers IGFBP-1 production. Further, we observed downregulation of the tumour-suppressor phosphatase and tensin homolog in schwannoma cells leading to increased activity of antiapoptotic AKT. Thus, IGFBP-1/integrin b1/Src/FAK pathway has a crucial role in merlin-related tumourigenesis and therefore represents an important therapeutic target in the treatment of merlin-deficient tumours.
Introduction
Mutations in the NF2 (neurofibromatosis 2) gene coding for the tumour-suppressor merlin leads to the development of a variety of tumours of the nervous system such as schwannomas, meningiomas and ependymomas occurring spontaneously or as part of inherited tumour disorder NF2. Schwannomas are the most frequent merlin-deficient tumours. Merlin belongs to the ERM (ezrin-radixin-moesin) family proteins (Rouleau et al., 1993; Bretscher et al., 2002) connecting actin cytoskeleton and membrane proteins and is crucial for the regulation of signalling pathways for maintaining normal cell function (Morrison et al., 2007; Okada et al., 2007; McClatchey and Fehon, 2009) . Currently, there is no medical treatment for merlin-deficient tumours. To study schwannoma pathobiology and define therapeutic targets, we used our human in vitro model for schwannoma. We showed that plateletderived growth factor receptor b (PDGFRb) and ErbB2/3 are overexpressed/activated in schwannoma in vitro and in vivo leading to strong/long-lasting activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT (Fraenzer et al., 2003; Ammoun et al., 2008 Ammoun et al., , 2010a Hilton et al., 2009) . ERK1/2 activation increases schwannoma proliferation (Ammoun et al., 2008 (Ammoun et al., , 2010b . Survival is also augmented in schwannoma (Utermark et al., 2005) because of the activity of ErbB2/3 and survivin (Ammoun et al., 2010a) . Pathologically increased cell-matrix adhesion in schwannoma is dependent on overexpressed/activated integrins but is completely independent of PDGFRb, suggesting that other factors are involved Ammoun et al., 2008) . Furthermore, schwannoma cells display elevated basal (non-stimulated) activity of ERK1/2, AKT and focal-adhesionkinase (FAK) (Ammoun et al., 2008) and increased basal proliferation, which is only partly dependent on PDGFRb (Ammoun et al., 2008) and is independent of ERK1/2 and ErbB2/3 (Ammoun et al., 2008 (Ammoun et al., , 2010a suggesting the involvement of other important factors. Our aim was to identify targets relevant in basal proliferation and cell-matrix adhesion of schwannomas.
Previously, we showed that insulin-like growth factor-binding protein-1 (IGFBP-1) is overexpressed in schwannoma, detected by DNA array and reverse transcriptase-PCR (Hanemann et al., 2006) . As shown in other cancer models IGFBP-1, through its COOHterminal RGD motif (Jones et al., 1993b; Yee, 2002) , can act via b1-integrin toward FAK (Zumkeller and Westphal, 2001; Zhang and Yee, 2006; Perks et al., 2007) both strongly overexpressed and basally activated in schwannoma Ammoun et al., 2008) and may potentiate cell proliferation, migration and survival (Giancotti and Ruoslahti, 1999) . Therefore, we wondered what role IGFBP-1 has in schwannoma development. Phosphorylated-IGFBPs interact with insulin-like growth factors (IGFs)/IGF receptor-I signalling and may either potentiate or impair IGF receptor-I activation (Chaves and Saif, 2011 ). In contrast to phosphorylated form, non-phosphorylated IGFBPs, act via integrins, independently on IGFs and are known to contribute to tumour growth via autocrine release (Schutt et al., 2004 ). We here demonstrate that schwannoma, in contrast to Schwann cells, release nonphosphorylated IGFBP-1, which activates the Src/FAK pathway via b1-integrin potentiating schwannoma proliferation and cell-matrix adhesion. We show that FAK localizes to the nucleus being involved in schwannoma proliferation and Src triggers IGFBP-1 production. Further, we observed downregulation of the tumoursuppressor phosphatase and tensin homolog (PTEN) in schwannoma leading to increased activity of antiapoptotic AKT. Thus, IGFBP-1/b1-integrin/Src/FAK pathway represents an important therapeutic target in the treatment of merlin-deficient tumours.
Results

IGFBP-1 is upregulated and released only from schwannoma cells
We show strong overexpression and release of IGFBP-1 from schwannoma but not Schwann cells, using enzymelinked immunosorbent assay (ELISA) assay and western blotting ( Figure 1a , left and right panels). The specificity of the IGFBP-1 expression detected by western blot is shown in Figure 1a (right upper panel), using blocking peptide. As there are no known housekeeping proteins in media, we used unspecific bands as well as corresponding ponceau S staining, as a loading control (Supplementary Figure 1) . Merlin reintroduction quenched IGFBP-1 production and release ( Figure 1b , left and right panels) without affecting cell viability (data not shown). Using antibody detecting both phospho and non-phospho IGFBP-1 and l-phosphatase, we demonstrate that IGFBP-1 released from schwannoma cells is in its non-phosphorylated state as phosphatase treatment did not lead to a shift in molecular weight Figure 1c (upper and middle panels). There was no difference whether the cells were cultured in complete medium (growth factor medium, GFM) containing serum (Figure 1c, upper panel) or serum-free medium (Dulbecco's modified Eagle's medium (DMEM)) ( Figure 1c , middle panel). Phosphatase functionality was confirmed in Figure 1c (bottom panel) where decreased phosphorylation of ERK1/2, using the same cultures, was shown.
Our in vitro data were confirmed in vivo in formalinfixed schwannoma tissue sections demonstrating cytoplasmic and some nuclear immunoreactivity of nonphosphorylated IGFBP-1 (Figure 1d , upper left panel and Figure 1d , middle left panel). Normal nerve (Figure 1d , upper right panel) and traumatic neuroma (Figure 1d , middle right panel) expressed IGFBP-1 weakly compared with schwannoma. As IGFBP-2 acts via the same integrins as IGFBP-1 (Perks et al., 2007) , displaying some similarities in signalling (Wheatcroft and Kearney, 2009 ), we tested whether Schwann and schwannoma cells release IGFBP-2. We demonstrated that both cell types release IGFBP-2 equally (Figure 1e ). IGFBP-2 may possibly potentiate IGFBP-1 signalling in schwannoma. As IGFBP-1 is released from schwannoma cells and is not detectable in Schwann cells we have, in this study, used IGFBP-1 for further analysis.
a5-integrin is expressed in schwannoma and Schwann cells Non-phosphorylated IGFBP-1 acts independently of IGFs (Jones et al., 1993a) via a5/b1-integrins (Wheatcroft and Kearney, 2009). Integrin b1 is overexpressed in schwannoma cells . Here, we demonstrate expression of a5 in schwannoma and Schwann cells (Figure 2a) . Thus the receptor, through which IGFBP-1 can act, independently of IGFs, is expressed on schwannoma cells. We have therefore investigated the role of IGFBP-1 and its connection with a5/b1-integrin in human schwannoma.
Non-phosphorylated IGFBP-1 increases schwannoma proliferation and adhesion by recruiting b1-integrin As IGFBP-1 synthesis was not observed in Schwann cells (Figure 1a) , we preceded our investigations in schwannoma cells. First, we investigated mitogenic and pro-adhesive effects of IGFBP-1 on schwannoma cells and the role of integrin b1.
Proliferation. We show that recombinant (non-phosphorylated) IGFBP-1(0.1-100 ng/ml) (Figure 2b ) is mitogenic for schwannoma cells. Recombinant IGFBP-1 increased basal schwannoma cell proliferation by B40%, after 24-h stimulation, which was significant but lower than the proliferation caused by complete medium (GFM) containing fetal calf serum, insulin and heregulin ( Figure 2b Despite only non-phosphorylated IGFBP-1 was detected in schwannoma in vitro and in vivo, phosphorylated form could be present in the blood circulation. We thus tested native (phosphorylated) human IGFBP-1, which did not increase basal proliferation of schwannoma cells (Figure 2d ). We have therefore continued our study using non-phosphorylated recombinant human IGFBP-1.
Adhesion. Recombinant IGFBP-1 (100 ng/ml) strongly potentiated schwannoma cell-matrix adhesion, almost to the same extension as complete medium (GFM) (Figure 2e, left panel) . Knock down of b1-integrin 
. Schwannoma cells were cultured for 3 days, the supernatant collected and IGFBP-1 detected using enzyme-linked immunosorbent assay (ELISA) (left panel) and western blotting (right panel) (n ¼ 13). (b) IGFBP-1 synthesis and release is regulated by merlin. Cells were infected with mock adenovirus and adenovirus containing wild-type merlin (described in Materials and methods section). After 24 h, medium was collected and cells lysed (Xiao et al., 2005) . (c) IGFBP-1 is released in non-phosphorylated state (upper and middle panels; n ¼ 6). Complete culture medium (GFM) (upper panel) or serum-free medium (DMEM, middle pane) collected from schwannoma cells and cell lysates were treated with lambda phosphatase and levels of phosphorylated IGFBP-1 in medium and phosphorylated ERK1/2 in cell lysates (positive control for phosphatase activity) were monitored by western blotting (bottom panel). Short-term stimulation with recombinant IGFBP-1 upregulates phosphorylation of FAK but not ERK, AKT and JNK in b1 integrin-mediated manner Next, we investigated the effects of IGFBP-1 on FAK, ERK, AKT and c-Jun N-terminal kinase (JNK) phosphorylation previously shown to be strongly activated in basal conditions in schwannoma cells Ammoun et al., 2008) . In order to have well-controlled system, we starved cells for 24 h, then medium was changed to fresh DMEM for 30 min to minimize autocrine-mediated signalling and cells were stimulated with recombinant IGFBP-1. We demonstrate that short stimulations (5 min) of schwannoma cells with recombinant IGFBP-1 had no effect on neither ERK 1/2 ( Figure Only non-phosphorylated IGFBP-1 mediates schwannoma proliferation and adhesion via a5/b1-integrin (a) Integrin a5 is equally expressed in human primary Schwann (NF2 þ / þ ; n ¼ 6) and schwannoma (NF2 À/À ; n ¼ 6) cells. (b) Recombinant (nonphosphorylated) IGFBP-1 increases schwannoma cells but not Schwann cells proliferation. Cells were cultured in DMEM only and DMEM containing 100 ng/ml IGFBP-1 (first and third panels) and 0.1 ng/ml-100 ng/ml IGFBP-1 (second panel) for 24 h. Cell amount was determined by 4,6-diamidino-2-phenylindole (DAPI) staining (first and second panels) and by BrdUrd incorporation (third panel). (c) shRNA IGFBP-1 (clone 17) decreased basal proliferation of schwannoma cells (left panel) and shRNA integrinb1 (clones 86 and 96) decreased both basal and IGFBP-1-mediated proliferation (right panel). (d) Native phosphorylated IGFBP-1 is not mitogenic for schwannoma cells. Cells were cultured in DMEM only and DMEM containing 100 ng/ml native-IGFBP-1for 24 h and proliferation determined by DAPI staining. (e) Recombinant (non-phosphorylated) IGFBP-1 increases cell-matrix adhesion of schwannoma cells (left panel n ¼ 8) via b1-integrin (right panel n ¼ 3). shRNA was used to knock down b1-integrin (right panel). In all figures but (a), the data are normalized to the basal (non-stimulated levels), in (a) to Schwann cells (NF2 þ / þ ), in (e) (right panel) IGFBP-1-stimulated mock shRNA is normalized to basal mock shRNA and IGFBP-1-stimulated shRNA b1 to basal shRNA b1. GFM (complete culture medium contains: DMEM, fetal calf serum (FCS), forskolin, b-heregulin, 3-isobutyl-1-methylxanthine (IBMX) and insulin) (*Po0.05, **Po0.01, ***Po0.001).
IGFBP-1 in human schwannoma S Ammoun et al (Figure 2b , first and second panels). Native IGFBP1 did not lead to increased FAK activity (see Supplementary Figure S2 ). shRNA IGFBP-1 abolished FAK phosphorylation at Tyr397 in schwannoma cells without affecting FAK expression (Figure 2b , third panel). b1-integrin shRNA completely abolished IGFBP-1-mediated FAK phosphorylation at Tyr397 (Figure 2b , fourth panel). We used RhoGDI as a loading control since we have previously shown that this protein, in contrast to cytoskeleton proteins, for example, actin or tubulin, is not regulated in schwannoma cells (Hanemann et al., 2006; Ammoun et al., 2008) .
PTEN is downregulated in schwannoma via IGFBP-1 PTEN is a tumour suppressor downregulated in many cancers (Li et al., 1997) and has been shown to be downregulated by IGFBP-2 acting, similarly to IGFBP-1, via a5/b1-integrins (Perks et al., 2007) . We have therefore investigated the expression of PTEN in schwannoma cells compared with Schwann cells and the role of IGFBP-1. We showed that PTEN expression is downregulated in schwannoma cells compared with Schwann cells (Figure 3c , left panel). IGFBP-1 significantly decreased PTEN expression in human schwannoma cells (Figure 3c , right panel). As PTEN is an endogenous negative regulator of AKT activity we investigated whether IGFBP-1-mediated downregulation of PTEN would lead to the increased AKT activity. We showed that long-term (48 h) stimulation of schwannoma cells with IGFBP-1 resulted in a significant increase in AKT phosphorylation (Figure 3d ).
IGFBP-1 stimulates Src activity via b1-integrin and has a positive feedback from Src Our results suggest that FAK, which is overexpressed and basally activated in schwannoma (Ammoun et al., 2008) likely together with Src are important kinases downstream of IGFBP-1 and a5/b1-integrins. We have therefore investigated Src activity in our cells. We demonstrate that schwannoma cells display increased Src activity compared with Schwann cells (Figure 4a ). Granular cytoplasmic staining of phospho-Src Tyr416 was also observed in human schwannoma tissue sections Addition of recombinant IGFBP-1 to schwannoma cells clearly potentiated Src activity by approximately 50%, which is significant but lower than that stimulated by 10% fetal calf serum (Figure 4b, first panel) . shRNA IGFBP-1 strongly decreased Src activity (Figure 4b,  second panel) . Further, IGFBP-1-mediated phosphorylation of Src involves integrin b1 shown using shRNA and western blotting (Figure 4b, third panel) . Src upregulates IGFBP-1 mRNA in human endometrial stromal cells (Nagashima et al., 2008) . Interestingly, the inhibition of Src by SU6656 (4 mM) decreased the release of IGFBP-1 from schwannoma cells by B60% (Figure 4c , left panel) without affecting cell viability (Figure 4c , right panel). The inhibition of FAK phosphorylation at Tyr925 by Src inhibitor SU6656 (4 mM) is shown in Figure 4d .
As Src activity is increased in schwannoma cells, compared with Schwann cells, activating FAK on IGFBP-1 stimulation and regulating synthesis and release of IGFBP-1 in schwannoma cells, we suggest the existence of a potential positive feedback loop in those cells potentiating Src activity.
Src/FAK pathway regulates recombinant IGFBP-1-mediated proliferation and adhesion of schwannoma cells b1-Integrin triggers autophosphorylation of FAK at Tyr395 and recently it has been shown that FAK translocates to the nucleus in human carcinoma cells (Lim et al., 2008a) . Moreover, FAK small inhibitors reduced tumour cells growth in vivo (Lim et al., 2008b) . Our present study showed that FAK is activated by recombinant IGFBP-1 (Figure 3b , first and second panel) and that Src, an important FAK activator, is activated in schwannoma cells (Figure 4a , upper left and right panel) regulating IGFBP-1 synthesis and release (Figure 4c, left panel) . We have therefore investigated whether Src/FAK pathway is involved in IGFBP-1-mediated schwannoma proliferation and adhesion. 4) . In all western blots but (c) (left panel), where GAPDH was used as a loading control, RhoGDI was used as a loading control (Hanemann et al., 2006; Ammoun et al., 2008 Ammoun et al., , 2010b . In (c) (left panel), the data are normalized to Schwann cells (NF2 þ / þ ) and in the rest of experiments to the basal (non-stimulated) levels. In (c) and (d), the cells were cultured in serum-free medium for 48 h in presence or absence of recombinant IGFBP-1 (200 ng/ml). In the rest of experiments, the cells were serum starved for 24 h and then stimulated for 5 min with recombinant IGFBP-1 (100 ng/ml). The levels of phosphorylated FAK, ERK1/2, AKT and JNK and the expression of IGFBP-1, integrin b1 and PTEN were monitored by western blotting. N represents number of samples from different patients (*Po0.05, **Po0.01, ***Po0.001). Our data showed that PI3K/AKT pathway indeed has a pro-survival role in human primary schwannoma as both inhibitors significantly decreased cell viability (Figure 5c ).
IGFBP-1 in human schwannoma
Adhesion. Similarly to the proliferation, recombinant IGFBP-1-mediated cell-matrix adhesion is also Src/ FAK dependent as it was completely inhibited by Src inhibitor SU6656 (1 mM) and almost completely inhibited by FAK inhibitor PF573228 (100 nM) (Figure 5d ).
Discussion
Here, we demonstrate that IGFBP-1 is overexpressed and released from schwannoma but not Schwann cells as shown in both human primary cells and tissues ( Figure 6 ). Interestingly, we have only detected the nonphosphorylated form of IGFBP-1. This could be due to the following reasons: (1) IGFBP-1 dephosphorylation by phosphatases present outside of the cell as previously reported by Jones et al. (1991) . (2) IGFBP-1 could be released in non-phosphorylated form as in amniotic fluids or human fetal serum (Jones et al., 1991) . As we show IGFBP-1 presents in significant amounts in the non-phosphorylated form, which is not relevant for IGF-dependent signalling (Jones et al., 1991) . We have therefore focused on IGF-independent signalling of IGFBP-1 and effects of non-phosphorylated recombinant rather than phosphorylated native IGFBP-1. Our previous and current data showed that in addition to the overexpression and release of IGFBP-1 from schwannoma cells, receptors mediating IGFBP-1 signallinga5/ b1-integrins are also expressed . Importantly, we show that IGFBP-1 is mitogenic and increases adhesion in schwannoma cells. We investigated FAK, ERK1/2 and AKT previously known to be upregulated and basally activated in schwannoma Ammoun et al., 2008) . We show that IGFBP-1 triggers FAK phosphorylation at its autophosphorylation site Tyr397 and at Src phosphorylation site Tyr925 (Figure 6 ). Interestingly, activity of ERK1/2, AKT and JNK are not potentiated on short-term IGFBP-1 stimulation. We suggest that IGFBP-1, acting via a5/b1-integrins, leads to the increased autophosphorylation of FAK at Tyr397 (Leu and Maa, 2002 ) and activation of Src, which further potentiates FAK phosphorylation at Tyr925 (Figure 6 ). FAK phosphorylated at Tyr925 creates SH2-binding site for growth factor receptor-bound protein 2, which couples FAK to the Ras/Raf/MEK/ERK pathway (Schlaepfer et al., 1994) . However, as neither ERK1/2 nor JNK activity/phosphorylation is increased by IGFBP-1, the role of FAK phosphorylation at Tyr925 is difficult to explain. AKT activity/phosphorylation is slightly decreased on short-term stimulation with recombinant IGFBP-1. As AKT is activated on phosphorylation of Thr308 and Ser473, the short-term decrease in AKT phosphorylation could be due to acute activation of Ca 2 þ -calmodulin-activated serine/threonine protein phosphatase calcineurin (Lin et al., 2003; Park et al., 2008) . Interestingly, prolonged stimulation of schwannoma cells with recombinant IGFBP-1 increases AKT activity ( Figure 6 ). As PTEN is an important AKT antagonist regulating cell growth (Blanco-Aparicio et al., 2007; Liu et al., 2008; Feron et al., 2009) (Perks et al., 2007) , IGFBP-1 also contributes to the downregulation of PTEN (Figure 6 ). Thus, based on our data we here demonstrate a novel mechanism involved in schwannoma development via autocrine release of IGFBP-1, which downregulates PTEN leading to increased AKT activity and survival of schwannoma cells ( Figure 6 ). As PTEN degradation is regulated by polyubiquitination in the cytoplasm (Trotman et al., 2007) , restoring PTEN protein level by ubiquitinproteasome pathways inhibitors could be an important antitumour therapeutic option for schwannoma. In addition to the decreased PTEN expression, the increase in AKT activity could be due to PIKE (phosphatidylinositol 3-kinase (PI3-kinase) enhancer) activation caused by merlin-deficiency as previously described by Rong et al. (2004) . As IGFBP-1 contributes to the increased basal AKT and FAK but not to previously shown ERK1/2 and JNK activity in schwannoma cells, we suggest that other growth factors must be involved in addition to IGFBP-1. One such growth factor is PDGF as we have previously shown that its receptor PDGFR inhibitor AG1296 significantly, but only partially, inhibits basal AKT, ERK and proliferation of schwannoma cells (Ammoun et al., 2008) . As Src-mediated phosphorylation of FAK is caused by IGFBP-1 (Figure 6 ), and Src, acts in complex with FAK (Schlaepfer et al., 2004; Mitra and Schlaepfer, 2006) we have further investigated Src activity and its role in IGFBP-1-mediated signalling. We show that Src activity is significantly increased in schwannoma compared with Schwann cells. Moreover, Src is responsible for IGFBP-1 synthesis and release in schwannoma cells as previously described by Nagashima et al. (2008) in human endometrial stromal cells. Thus, Src seems to be important for IGFBP-1/a5/b1/FAK-mediated schwannoma pathobiology. Importantly, our results agree with previously published data demonstrating the role of active Src in NF2 À/À mouse astrocyte cell proliferation recruiting active FAK and paxillin (Houshmandi et al., 2009) . We have further investigated the functional role of IGFBP-1 and Src/FAK pathway. Our data IGFBP-1 in human schwannoma S Ammoun et al Figure 4 The role of Src in IGFBP-1 signalling and release. (a) Src is strongly activated in human primary schwannoma (NF2 À/À ) (n ¼ 9) compared with Schwann (NF2 þ / þ ) cells (n ¼ 6) (left panel). Cells were starved for 24 h, lysed and Src activity determined in cell lysates using western blotting (left panel). Human schwannoma tissues express phospho-Src Tyr416, predominantly distributed in the cytoplasm (right panel, first upper picture). Phospho-Src Tyr416 staining is eliminated with phosphatase (right panel, second upper picture) and is specific (right panel, third upper picture). Normal Schwann cells (right panel, first bottom picture) and traumatic neuroma (right panel, first bottom picture) expressed Phospho-Src (Tyr416) very weakly. (b) Src activity in schwannoma cells is potentiated by recombinant IGFBP-1 (n ¼ 6) (first panel). Fetal calf serum (FCS) stimulates Src slightly stronger than IGFBP-1 (first panel). The cells were serum-starved for 24 h and treated with recombinant IGFBP-1 (100 ng/ml) or with 10% FCS for 5 min. The activity of Src was determined by western blotting. shRNA IGFBP-1 strongly inhibits Src phosphorylation at Tyr416 (second panel). The IGFBP-1 knock-down efficiency is shown using anti-IGFBP1 antibody (second panel, upper picture). The IGFBP-1-mediated activation of Src proceeds via integrin b1 (third panel). Integrin b1 knock-down efficiency is shown using anti-b1 antibody in third panel upper picture. (c) Src inhibitor SU6656 (4 mM) strongly decreases IGFBP-1 release form schwannoma cells (n ¼ 4). Cells were cultured in serum-free medium (DMEM) in the presence or absence of SU6656 (4 mM) for 24 h. Cell supernatants were collected and the levels of released IGFBP-1detected using enzyme-linked immunosorbent assay (ELISA) (left panel). Cell viability is not affected by Src inhibitor SU6656 (4 mM) (right panel). Cell viability was determined using 4,6-diamidino-2-phenylindole (DAPI) (1 mg/ ml) and propidium iodide (PI) (2.5 mg/ml) staining. (d) SU6656 (4 mM) decreases the phosphorylation of FAK at Tyr925. Cells from (d), after being treated with SU6656 (4 mM) for 24 h, were stimulated with recombinant IGFBP-1 (100 ng/ml) for 5 min and lysed. Phospho-FAK Tyr 925 was detected by western blotting. In (a) (left panel), the data are normalized to Schwann cells (NF2 þ / þ ). In (b) (first panel), the data are normalized to the basal (non-stimulated) levels, in (b) (second panel) normalization is to mock shRNA-infected cells and in (b) (third panel) to basal mock shRNA-infected cells. In (a) and (b), RhoGDI is used as a loading control as previously described in (Hanemann et al., 2006) . N represents number of samples from different patients (*Po0.05, **Po0.01).
IGFBP-1 in human schwannoma
S Ammoun et al demonstrate that recombinant (non-phosphorylated) IGFBP-1 stimulates proliferation of schwannoma cells involving b1/Src/FAK pathway (Figure 6 ). The increase in proliferation was, however, not as strong as with complete medium (GFM) containing fetal calf serum, insulin and heregulin, suggesting that other factors act . The cells were cultured in serum-free medium (DMEM) with/or without recombinant IGFBP-1 (100 ng/ml), Src inhibitor SU6656 (1 mM) and FAK inhibitor PF573228 (100 nM) for 24 h. Neither of inhibitors affected cell viability (second panel). In third panel, shRNA FAK and mock shRNA were used. . In all experiments, total cell number was counted using 4,6-diamidino-2-phenylindole (DAPI) (1 mg/ml) staining. Number of dead cells was determined using propidium iodide staining (PI) (2.5 mg/ml). (b) In schwannoma cells, FAK localizes in the nucleus (n ¼ 3) as shown by immunocytochemistry using anti-FAK antibody detected by secondary C3-labelled antibody. PhalloidinAlexa Fluor 488 antibody was used to visualize actin filaments and DAPI (5 mg/ml) for nuclear staining. Staining specificity was determined using FAK shRNA (left panel control mock shRNA and right panel shRNA FAK). (c) AKT pathway is pro-survival in schwannoma cells as shown by AKT-in inhibitory peptide (NH2-AVTDHPDRLWAWEKFCOOH encompassing the A strand of human TCL1 interacting and specifically inhibiting AKT kinase activity) and PI3 K inhibitor LY294002 (Hiromura et al., 2004) . The cells were cultured in serum-free medium (DMEM) in the presence of AKT-in peptide, mock (amino acid positions 29-40 of human TCL1 not binding to AKT) or LY294002 for 48 h. Cell viability was monitored by propidium iodide (PI) (2.5 mg/ml). (d) IGFBP-1-mediated schwannoma cell-matrix adhesion recruits Src/FAK pathway (n ¼ 3). Cells were starved for 24 h, detached, pretreated with SU6656 (1 mM) or PF573228 (100 nM), stimulated with recombinant IGFBP-1 (100 ng/ml) and re-plated. Attached cells were monitored with DAPI (1 mg/ml). In all experiments, the data are normalized to the basal (non-stimulated) levels. In (a) (third panel), IGFBP-1-stimulated mock shRNA is normalized to basal mock shRNA and IGFBP-1-stimulated shRNA FAK to basal shRNA FAK. N represents number of samples from different patients (*Po0.05, **Po0.01).
S Ammoun et al in concert with IGFBP-1. Interestingly, Schwann cells do not proliferate on IGFBP-1 stimulation probably due to lower Src activity and b1-integrin expression compared with schwannoma cells. Our data suggest that basal proliferation is at least partly due to the released IGFBP-1 involving integrin b1/Src/FAK pathway, which is a novel mechanism for schwannoma. FAK, when autophosphorylated can translocate to the nucleus and promotes cell proliferation and survival through FERM domain (FAK, ezrin, radixin, moesin) independently of kinase activity (Lim et al., 2008a) . Here, we demonstrate that FAK localizes to the nucleus in schwannoma cells (Figure 6 ), thus supporting its promitogenic capacity (Lim et al., 2008a) . Moreover, FAK knock down strongly decreased IGFBP-1-mediated proliferation of schwannoma cells. We suggest that inhibition of IGFBP-1-mediated proliferation is a potential therapeutic approach, as it would specifically target only tumour cells. Cell spreading is also potentiated by IGFBP-1 in schwannoma cells (Figure 6 ), which is an interesting and novel finding, as until now factors contributing to integrin-mediated cell-matrix adhesion of schwannoma were unknown. IGFBP-1-mediated cell-matrix adhesion follows the same pathway as proliferation involving integrinb1/Src/FAK pathway ( Figure 6 ). As long-term stimulation of schwannoma cells with recombinant IGFBP-1 leads to the increased AKT activity and we showed here that AKT is pro-survival in schwannoma cells, we suggest that IGFBP-1 have an anti-apoptotic role in schwannoma.
On the basis of the data presented in this paper, we suggest that integrin b1, Src and FAK represent good therapeutic targets in schwannoma. Inhibitors for these targets have been already tested either in phase I clinical trials or in various tumour models.
Moreover, the restoration of PTEN expression using ubiquitin-proteasome pathways inhibitors could be an additional therapeutic approach.
Materials and methods
Human primary Schwann and schwannoma cell isolation and culture Human primary Schwann and schwannoma cells were isolated and cultured in (GFM): DMEM, 10% fetal calf serum, 0. 5 mM forskolin, 10 nM b-heregulin, 0.5 mM 3-isobutyl-1-methylxanthine and 2.5 mg/ml insulin as described (Rosenbaum et al., 2000) . For every experiment at least three batches of primary cells from different patients were used. For some experiments samples from up to eight patients were tested. Chemicals SU6656 and LY294002 were from Calbiochem (La Jolla, CA, USA). PF-573228 from Pfizer Inc. (New York, NY, USA) and Akt-in was from Imgenex (San Diego, CA, USA). 4,6-Diamidino-2-phenylindole and propidium iodide were from Sigma (Poole, Dorset, UK). Human recombinant IGFBP-1 was from Cell Sciences (Canton, MA, USA), lprotein phosphatase from New England Biolabs (Ipswich, MA, USA). SU6656, PF-573228 and LY294002 inhibitors were added 40 min prior stimulation.
Immunoblotting Cells were serum starved for 24 h, stimulated and lysed (Utermark et al., 2005) . For the detection of the released IGFBP-1, cell culture medium was collected and western blotting performed in the same way as for cell lysates.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blotting were performed as previously described . Phosphorylated/activated proteins were detected by anti-phospho-Src (Tyr416) (Cell Signaling Technology, Danvers, MA, USA and Abcam, Cambridge, MA, USA), anti-active-MAPK (anti-pThr(183)-pTyr(185)-ERK1/2) (Promega, Madison, WI, USA), anti-phospho-AKT (Ser473) (Cell Signaling Technology), anti-phospho-FAK (Tyr925) (Cell Signaling Technology), anti-phospho-FAK (Tyr397) (Chemicon International, Temecula, CA, USA), anti-phospho-JNK (Thr183/Tyr185) (Cell Signaling Technology) primary antibodies. The expression of PTEN, integrin-a5, b1-integrin and release of IGFBP-1 and IGFBP-2 were detected by anti-PTEN (Cell Signaling Technology), anti-human integrin-a5/CD49e (R&D Systems, Abingdon, UK), anti-b1-integrin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-IGFBP-1 (Upstate, Lake Placid, NY, USA) and anti-IGFBP-2 (Santa Cruz Biotechnology) antibodies. Appropriate horseradish peroxidase-conjugated secondary antibodies were used (Bio-Rad, Hercules, Hertfordshire, UK). ECL-plus (Amersham, Buckinghamshire, UK) was utilized for detection. Rho-GDI was used as a loading control, (anti-RhoGDI antibody; Santa Cruz Biotechnology), as it has previously been shown not to be regulated in our system (Hanemann et al., 2006; Ammoun et al., 2008) . In one occasion, anti-GAPDH antibody (Millipore, Billerica, MA, USA) was used as a loading control. In western blots performed on culture media, nonspecific bands were used as a loading control as they correspond to total protein levels detected by ponceau S (Supplementary Figure 1) .
Non-sodium dodecyl sulphate-polyacrylamide gel electrophoresis for the detection of released IGFBP-1 was performed as previously described in Jones et al. (1991) using anti-human- Figure 6 Signalling pathways involved in increased proliferation, cell-matrix adhesion and survival of schwannoma cells mediated by IGFBP-1 and a5/b1 integrins. Schwannoma cells display increased basal Src and FAK activity (Ammoun et al., 2008) . Active Src leads to the production and release of IGFBP-1. The released IGFBP-1 acts in autocrine manner via a5/b1-integrins potentiating the autophosphorylation/activation of FAK at Tyr397 increasing schwannoma cell-matrix adhesion. FAK is also translocated into the nucleus leading to the increased schwannoma proliferation in Src-dependent manner. Elevated IGFBP-1 concentrations released from schwannoma leads to the decreased levels of tumour-suppressor PTEN and increased pro-survival AKT activity.
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